Absent antibody production following COVID19 vaccination with mRNA in patients under immunosuppressive treatments. Issue 51 (17th December 2021)

• Record Type: Journal Article
• Authors: Wagner, Angelika; Jasinska, Joanna; Tomosel, Elena; Zielinski, Christoph C.; Wiedermann, Ursula
• Is Part Of: Vaccine. Volume 39:Issue 51(2021)
• Page Start: 7375
• Page End: 7378
• Publication Date: 2021-12-17
• Subjects: Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2021.10.068
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Patients undergoing immunosuppressive treatments have a higher need for protection against coronavirus disease (COVID19) that follows infection with the SARS-CoV-2 virus but their ability to respond sufficiently to COVID vaccines is uncertain. We retrospectively evaluated SARS-CoV-2 spike subunit 1 (S1)-specific antibody levels after two mRNA doses in 242 patients with underlying chronic inflammatory, hematooncological or metabolic diseases and in solid organ transplant recipients. S1-specific antibodies were measured 30 days after the second dose. In 15.9% of these patients, no S1-specific antibodies were detectable. Non-responsiveness was linked to administration of B-cell depleting therapies as well as to ongoing therapies that block lymphocyte trafficking (Fingolimod) or inhibit T cell proliferation (Tacrolimus). Thus, it is important to inform immunosuppressed patients about the risk of vaccine non-responsiveness and the necessity to maintain non-pharmaceutical protection measures. In these risk patients antibody testing and cellular analysis are helpful to estimate the benefit/responsiveness to further booster vaccinations.